No Data
No Data
Here's Why Shareholders May Want To Be Cautious With Increasing Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Pay Packet
Key Insights Oncternal Therapeutics' Annual General Meeting to take place on 20th of June Salary of US$609.4k is part of CEO Jim Breitmeyer's total remuneration The overall pay is 44% above the in
Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX), Cyclo Therapeutics (CYTH) and Oncternal Therapeutics (ONCT)
Express News | HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price Target
Express News | Oncternal to Provide Onct-534 Study Update Q3 2024
Express News | Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
No Data